Pharmaceutical Stock Jumps 26% on Crypto Pivot Plan
TLDR NovaBay Pharmaceuticals Inc announced it will rebrand as Stablecoin Development Corporation and adopt the ticker SDEV. The company confirmed it will shift from pharmaceutical operations to a digital asset holding model. Shares of the Pharmaceutical stock surged 26.29% to $1.46 after the announcement. The stock later traded at $1.38 at press time following the initial rally. The company holds about 2.06 billion SKY tokens, equal to 8.78% of the total supply. NovaBay Pharmaceuticals Inc announced plans to exit pharmaceuticals and adopt a digital asset strategy. The company will rebrand as Stablecoin Development Corporation and change its ticker to SDEV in early April. Shares rose 26.29% to $1.46 before easing to $1.38, while SKY token gained 6.73% to $0.0728. Pharmaceutical Stock Reacts to Sky Ecosystem Pivot NovaBay Pharmaceuticals Inc (NYSE: NBY) confirmed on March 23 that it will rebrand as Stablecoin Development Corporation. The company will shift from eye care and anti-infective products to an on-chain holding company model. It expects the new SDEV ticker to begin trading in early April. The company will anchor its strategy in the Sky protocol ecosystem, formerly known as Maker. Sky operates a decentralized finance network built around the USDS stablecoin and SKY governance token. NovaBay stated that it aims to position itself as a public market gateway into stablecoin-based finance. Shares responded immediately to the announcement and climbed 26.29% to $1.46. However, the price later pulled back and traded at $1.38 at press time. SKY token traded 6.73% higher at $0.0728 during the same period. SKY Token Strategy Drives New Corporate Model Stablecoin Development Corporation disclosed that it holds about 2.06 billion SKY tokens. The company said this stake represents roughly 8.78% of the total SKY supply. It also reported earning 26.6 million SKY tokens through staking rewards. The company stated that it has deployed capital into on-chain yield strategies ...
Comments
Log in to comment